Prevention of Syncope (fainting) Trial 11
Summary
About 20% of adults faint regularly. No treatments are proven useful in executed clinical trials. This is a study to test the theory that Ondansetron reduces the time to a recurrence of faint in a TILT test. In this study half the patients will receive Ondansetron the night before and the morning of the study day ( TILT Table test) the other half will receive a Placebo. you need to fill in two surveys. No follow-up needed after the study day.
Eligibility
Eligible ages: 18 to 99
Inclusion criteria:
1. ≥1 faints in the year preceding enrolment
2. Vasovagal Syncope
3. Age ≥ 18 years
Exclusion criteria:
(1) other causes of syncope, such as ventricular tachycardia, complete heart block, orthostatic hypotension or hypersensitive carotid sinus syndrome
(2) an inability to give informed consent
(3) important valvular, coronary, myocardial or conduction abnormality or significant arrhythmia
(4) hypertrophic cardiomyopathy
(5) a permanent pacemaker
(6) a seizure disorder
(7) hypertension defined as >160/90 mm Hg
(8) pregnancy
(9) lactating women
(10) glaucoma
(11) medications with known effects on BP
(12) Known hypersensitivity to ondansetron and related medications
(13) other factors which, in the investigator’s opinion, would prevent the subject from completing the protocol.
Participate
Fill out the following form if you want to participate in this research
UCalgary Notice of Collection
The University of Calgary (UCalgary) respects your privacy and is
committed to ensuring the privacy of all students, staff, and community members. Your personal information is being
collected under the authority of section 4(c) of the Protection of Privacy Act (POPA). It will be collected, used
and disclosed for the purposes outlined in UCalgary’s
Notice of
Collection, Use and Disclosure of Personal Information and managed in accordance with UCalgary’s
Privacy
Management Program.
Your personal information may be input into automated systems to generate content or make decisions,
recommendations, or predictions. If you have questions regarding this notice or UCalgary’s collection,
use, or disclosure of your personal information, please contact
accessandprivacy@ucalgary.ca.
Additional information
Contact information
Rasha Hamzeh Email: rasha.hamzeh1@ucalgary.ca Phone number:403-220-8897
Principal investigator:
Robert Stanley Sheldon
Clinical trial:
Yes
REB-ID:
REB23-0198